JP2006509015A5 - - Google Patents

Download PDF

Info

Publication number
JP2006509015A5
JP2006509015A5 JP2004557589A JP2004557589A JP2006509015A5 JP 2006509015 A5 JP2006509015 A5 JP 2006509015A5 JP 2004557589 A JP2004557589 A JP 2004557589A JP 2004557589 A JP2004557589 A JP 2004557589A JP 2006509015 A5 JP2006509015 A5 JP 2006509015A5
Authority
JP
Japan
Prior art keywords
groups
alkyl
optionally substituted
halo
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004557589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006509015A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/038590 external-priority patent/WO2004050039A2/en
Publication of JP2006509015A publication Critical patent/JP2006509015A/ja
Publication of JP2006509015A5 publication Critical patent/JP2006509015A5/ja
Withdrawn legal-status Critical Current

Links

JP2004557589A 2002-12-04 2003-11-26 スピロ環尿素、そのような化合物を含有する組成物、及び使用方法 Withdrawn JP2006509015A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43079902P 2002-12-04 2002-12-04
PCT/US2003/038590 WO2004050039A2 (en) 2002-12-04 2003-11-26 Spirocyclic ureas, compositions containing such compounds and methods of use

Publications (2)

Publication Number Publication Date
JP2006509015A JP2006509015A (ja) 2006-03-16
JP2006509015A5 true JP2006509015A5 (enExample) 2006-08-03

Family

ID=32469534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004557589A Withdrawn JP2006509015A (ja) 2002-12-04 2003-11-26 スピロ環尿素、そのような化合物を含有する組成物、及び使用方法

Country Status (6)

Country Link
US (1) US20060116366A1 (enExample)
EP (1) EP1569915A4 (enExample)
JP (1) JP2006509015A (enExample)
AU (1) AU2003298889A1 (enExample)
CA (1) CA2508581A1 (enExample)
WO (1) WO2004050039A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
SI1756064T1 (sl) * 2004-06-04 2008-12-31 Merck & Co Inc Derivati pirazola, sestavki vsebujoäśi takĺ ne sestavine in postopki uporabe
DE602005017895D1 (de) * 2004-07-07 2010-01-07 Merck & Co Inc Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
AU2005269792B9 (en) 2004-07-22 2008-11-27 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
CA2615656A1 (en) 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
JP2009502923A (ja) 2005-07-26 2009-01-29 メルク エンド カムパニー インコーポレーテッド 置換ピラゾールを合成するための方法
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
WO2007111864A2 (en) 2006-03-23 2007-10-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CA2650619A1 (en) 2006-05-16 2007-11-29 Merck And Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8293759B2 (en) 2006-10-30 2012-10-23 Merck, Sharp & Dohme, Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
MX2009008534A (es) 2007-02-09 2009-11-23 Metabasis Therapeutics Inc Antagonistas novedosos del receptor de glucagon.
EP2799428B1 (en) 2008-08-13 2016-11-16 Metabasis Therapeutics, Inc. Glucagon antagonists
WO2011119559A1 (en) * 2010-03-25 2011-09-29 Schering Corporation Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use
JP2013523642A (ja) * 2010-03-26 2013-06-17 メルク・シャープ・エンド・ドーム・コーポレイション グルカゴン受容体拮抗薬としての新規なスピロイミダゾロン誘導体、組成物およびそれらの使用方法
JP2014040374A (ja) * 2010-12-15 2014-03-06 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害物質
AU2011346670B2 (en) 2010-12-23 2015-05-07 Pfizer Inc. Glucagon receptor modulators
PH12013501557A1 (en) 2011-02-08 2019-06-03 Pfizer Glucagon receptor modulator
RU2013157388A (ru) 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
US8742111B1 (en) * 2013-02-21 2014-06-03 The United States Of America As Represented By The Secretary Of The Army Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics
EP3065736B1 (en) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
JP7155102B2 (ja) * 2016-07-07 2022-10-18 ブリストル-マイヤーズ スクイブ カンパニー Rock阻害剤としてのスピロ縮合環尿素
WO2018015235A1 (en) * 2016-07-18 2018-01-25 F. Hoffmann-La Roche Ag Ethynyl derivatives
JP2021513564A (ja) 2018-02-13 2021-05-27 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体拮抗薬
WO2021078132A1 (en) * 2019-10-21 2021-04-29 Sironax Ltd Inhibitors of mtor-mediated induction of autophagy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556670A (en) * 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications
FR2677984B1 (fr) * 1991-06-21 1994-02-25 Elf Sanofi Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
DE4201709A1 (de) * 1992-01-23 1993-07-29 Bayer Ag (alpha)-aryl-(alpha)-hydroxy-ss-imidazolinyl-propionsaeureamide
KR19990012061A (ko) * 1997-07-26 1999-02-25 성재갑 파네실 전이효소 저해제로 유용한 하이덴토인 유도체
US6384061B1 (en) * 1997-07-26 2002-05-07 Lg Chemical Ltd. Hydantoin compounds and methods related thereto

Similar Documents

Publication Publication Date Title
JP2006516622A5 (enExample)
TWI354666B (en) Heterocyclic aspartyl protease inhibitors
JP2005504042A5 (enExample)
JP2009530306A5 (enExample)
EA200800476A1 (ru) Макроциклические ингибиторы вируса гепатита с
JP2006515858A5 (enExample)
JP2010538076A5 (enExample)
RU2218337C2 (ru) Производные тиазола, способ их получения и фармацевтическая композиция на их основе
JP2005523310A5 (enExample)
CA2431952A1 (en) Muscarinic antagonists
JP2007510662A5 (enExample)
JP2006521359A5 (enExample)
RU2007139453A (ru) Гетеробициклические ингибиторы вируса гепатита с (hcv)
JP2013513613A5 (enExample)
RU2009126745A (ru) Производные сульфонилфенил-2н-{1,2,4}оксадиазол-5-она, способы их получения и их применение в качестве фармацевтических средств
JP2004516314A5 (enExample)
RU2002107318A (ru) Новые фенилпиперазины
AR032569A1 (es) Ligandos del receptor de canabinoide
JP2007534702A5 (enExample)
RU2009110997A (ru) Инсектицидные бензамидины
JP2005517643A5 (enExample)
DE602004031722D1 (de) Kondensierte bizyklisch substituierte amine als histamin 3 rezeptor liganden
JP2004529145A5 (enExample)
JP2010535706A5 (enExample)
JP2011510072A5 (enExample)